Vis enkel innførsel

dc.contributor.authorOrrem, Hilde Lang
dc.contributor.authorNilsson, Per
dc.contributor.authorPischke, Søren Erik
dc.contributor.authorGrindheim, Guro
dc.contributor.authorGarred, Peter
dc.contributor.authorSeljeflot, Ingebjørg
dc.contributor.authorHusebye, Trygve Guttorm
dc.contributor.authorAukrust, Pål
dc.contributor.authorYndestad, Arne
dc.contributor.authorAndersen, Geir Øystein
dc.contributor.authorBarratt-Due, Andreas
dc.contributor.authorMollnes, Tom Eirik
dc.date.accessioned2019-01-29T13:21:43Z
dc.date.available2019-01-29T13:21:43Z
dc.date.created2018-09-30T14:32:08Z
dc.date.issued2018
dc.identifier.citationESC Heart Failure. 2018, 5 (3), 292-301.nb_NO
dc.identifier.issn2055-5822
dc.identifier.urihttp://hdl.handle.net/11250/2582856
dc.description.abstractAims Heart failure (HF) is an impending complication to myocardial infarction. We hypothesized that the degree of complement activation reflects severity of HF following acute myocardial infarction. Methods and results The LEAF trial (LEvosimendan in Acute heart Failure following myocardial infarction) evaluating 61 patients developing HF within 48 h after percutaneous coronary intervention‐treated ST‐elevation myocardial infarction herein underwent a post hoc analysis. Blood samples were drawn from inclusion to Day 5 and at 42 day follow‐up, and biomarkers were measured with enzyme immunoassays. Regional myocardial contractility was measured by echocardiography as wall motion score index (WMSI). The cardiogenic shock group (n = 9) was compared with the non‐shock group (n = 52). Controls (n = 44) were age‐matched and sex‐matched healthy individuals. C4bc, C3bc, C3bBbP, and sC5b‐9 were elevated in patients at inclusion compared with controls (P < 0.01). The shock group had higher levels compared with the non‐shock group for all activation products except C3bBbP (P < 0.05). At Day 42, all products were higher in the shock group (P < 0.05). In the shock group, sC5b‐9 correlated significantly with WMSI at baseline (r = 0.68; P = 0.045) and at Day 42 (r = 0.84; P = 0.036). Peak sC5b‐9 level correlated strongly with WMSI at Day 42 (r = 0.98; P = 0.005). Circulating endothelial cell activation markers sICAM‐1 and sVCAM‐1 were higher in the shock group during the acute phase (P < 0.01), and their peak levels correlated with sC5b‐9 peak level in the whole HF population (r = 0.32; P = 0.014 and r = 0.30; P = 0.022, respectively). Conclusions Complement activation discriminated cardiogenic shock from non‐shock in acute ST‐elevation myocardial infarction complicated by HF and correlated with regional contractility and endothelial cell activation, suggesting a pathogenic role of complement in this condition.nb_NO
dc.language.isoengnb_NO
dc.publisherWiley Open Accessnb_NO
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleAcute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shocknb_NO
dc.title.alternativeAcute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shocknb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber292-301nb_NO
dc.source.volume5nb_NO
dc.source.journalESC Heart Failurenb_NO
dc.source.issue3nb_NO
dc.identifier.doi10.1002/ehf2.12266
dc.identifier.cristin1616256
dc.description.localcode© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License.nb_NO
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal